Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| INSMED IncINSM · Entity 3174 | Chief Accounting Officer | January 03, 2020 | January 07, 2020 |
| Immunocore Holdings plcIMCR · Entity 4544 | SVP, FINANCE & CAO | February 17, 2026 | February 19, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
INSMED Inc
Report date January 03, 2020 · Filed January 07, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 14,374 |
Reported balance
After 2020-01-03 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2020-01-03 · Grant · Acquired 5,263 · Balance 14,374 F1: Restricted stock units granted pursuant to the Company's 2019 Incentive Plan. The Restricted Stock Units vest and become available as follows: twenty five (25%) percent on each anniversary of the date of grant for four years. F2: Each Restricted Stock Unit was granted on January 3, 2020, for no consideration, and represents a contingent right to receive one share of Common Stock. F3: Includes 2,751 shares acquired through the Company's 2018 Employee Stock Purchase Plan. |
| Common StockSEC Table I · non-derivative | Direct | 14,166 |
Reported balance
After 2020-01-03 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2020-01-03 · Tax withholding · Disposed 208 · Balance 14,166 F4: Shares withheld by the Company to satisfy tax withholding requirements on vesting of time-based restricted stock units. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.75 · Expires 2030-01-03 | Direct | 28,260 |
Reported balance
After 2020-01-03 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-01-03 · Grant · Acquired 28,260 · Balance 28,260 F5: Stock options granted under the Company's 2019 Incentive Plan. The options become exercisable based on the following vesting schedule: twenty-five percent (25%) on the first anniversary of the grant date and an additional twelve and one-half percent (12.5%) vest on the six month anniversary of the first anniversary date and each six month anniversary date thereafter through the fourth anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock units granted pursuant to the Company's 2019 Incentive Plan. The Restricted Stock Units vest and become available as follows: twenty five (25%) percent on each anniversary of the date of grant for four years.
F2: Each Restricted Stock Unit was granted on January 3, 2020, for no consideration, and represents a contingent right to receive one share of Common Stock.
F3: Includes 2,751 shares acquired through the Company's 2018 Employee Stock Purchase Plan.
F4: Shares withheld by the Company to satisfy tax withholding requirements on vesting of time-based restricted stock units.
F5: Stock options granted under the Company's 2019 Incentive Plan. The options become exercisable based on the following vesting schedule: twenty-five percent (25%) on the first anniversary of the grant date and an additional twelve and one-half percent (12.5%) vest on the six month anniversary of the first anniversary date and each six month anniversary date thereafter through the fourth anniversary of the date of grant.
Immunocore Holdings plc
Report date February 17, 2026 · Filed February 19, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 653 |
Last balance in matching sequence
After 2026-02-18 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2026-02-17 · Exercise / conversion · Acquired 1,351 · Balance 1,351 F1: Ordinary Shares may be represented by American Depositary Shares. Each American Depositary Share represents one Ordinary Share. Row 2 · 2026-02-18 · Sale · Disposed 698 · Balance 653 F1: Ordinary Shares may be represented by American Depositary Shares. Each American Depositary Share represents one Ordinary Share. F2: The shares were sold pursuant to a sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of restricted share units ("RSUs") . F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.18 to $32.72 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Restricted Share UnitsSEC Table II · derivative / convertible security | Direct | 4,054 |
Reported balance
After 2026-02-17 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-02-17 · Exercise / conversion · Disposed 1,351 · Balance 4,054 F4: Each RSU represents a contingent right to receive one Ordinary Share. F5: On February 17, 2025, the Reporting Person was granted 5,405 RSUs, vesting in four equal annual installments beginning February 17, 2026, subject to the Reporting Person's continuous service through each such vesting date. F1: Ordinary Shares may be represented by American Depositary Shares. Each American Depositary Share represents one Ordinary Share. |
| Restricted Share UnitsSEC Table II · derivative / convertible security | Direct | 7,411 |
Reported balance
After 2026-02-17 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-02-17 · Grant · Acquired 7,411 · Balance 7,411 F4: Each RSU represents a contingent right to receive one Ordinary Share. F6: The RSUs vest in four equal annual installments beginning February 17, 2027, subject to the Reporting Person's continuous service through each such vesting date. F1: Ordinary Shares may be represented by American Depositary Shares. Each American Depositary Share represents one Ordinary Share. |
| Employee Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $32.38 · Expires 2036-02-16 | Direct | 21,252 |
Reported balance
After 2026-02-17 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-02-17 · Grant · Acquired 21,252 · Balance 21,252 F7: 25% of the shares subject to the option award shall vest on February 17, 2027, and 6.25% of the shares subject to the option award shall vest in quarterly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date. F1: Ordinary Shares may be represented by American Depositary Shares. Each American Depositary Share represents one Ordinary Share. |
Filing footnotes · ownership attribution and instrument terms
F1: Ordinary Shares may be represented by American Depositary Shares. Each American Depositary Share represents one Ordinary Share.
F2: The shares were sold pursuant to a sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of restricted share units ("RSUs") .
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.18 to $32.72 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4: Each RSU represents a contingent right to receive one Ordinary Share.
F5: On February 17, 2025, the Reporting Person was granted 5,405 RSUs, vesting in four equal annual installments beginning February 17, 2026, subject to the Reporting Person's continuous service through each such vesting date.
F6: The RSUs vest in four equal annual installments beginning February 17, 2027, subject to the Reporting Person's continuous service through each such vesting date.
F7: 25% of the shares subject to the option award shall vest on February 17, 2027, and 6.25% of the shares subject to the option award shall vest in quarterly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 18, 2026 Filed Feb 19, 2026 22:00 UTC | Immunocore Holdings plc IMCR · Entity 4544 | SaleOrdinary Shares | 698 | $32.35 | $22,580.30 |
DisclosureSEC source: 0001779466-26-000002 · form4-02192026_050207.xml · nonDerivative · entry 2 GOLL JOHN · CIK 0001779466 · SVP, FINANCE & CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 653 F1 · security: Ordinary Shares may be represented by American Depositary Shares. Each American Depositary Share represents one Ordinary Share. F2 · shares: The shares were sold pursuant to a sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of restricted share units ("RSUs") . F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.18 to $32.72 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 22:00 UTC | Immunocore Holdings plc IMCR · Entity 4544 | GrantEmployee Share Option (Right to Buy) · Derivative | 21,252 | $0.00 Strike: $32.38 | $0.00 |
DisclosureSEC source: 0001779466-26-000002 · form4-02192026_050207.xml · derivative · entry 5 GOLL JOHN · CIK 0001779466 · SVP, FINANCE & CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,252 Underlying: Ordinary Shares · 21,252 shares Expires 2036-02-16 F7 · derivative.exercise_date: 25% of the shares subject to the option award shall vest on February 17, 2027, and 6.25% of the shares subject to the option award shall vest in quarterly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date. F1 · derivative.underlying: Ordinary Shares may be represented by American Depositary Shares. Each American Depositary Share represents one Ordinary Share. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 22:00 UTC | Immunocore Holdings plc IMCR · Entity 4544 | GrantRestricted Share Units · Derivative | 7,411 | $0.00 | $0.00 |
DisclosureSEC source: 0001779466-26-000002 · form4-02192026_050207.xml · derivative · entry 4 GOLL JOHN · CIK 0001779466 · SVP, FINANCE & CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,411 Underlying: Ordinary Shares · 7,411 shares Expires not disclosed F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one Ordinary Share. F6 · derivative.exercise_date: The RSUs vest in four equal annual installments beginning February 17, 2027, subject to the Reporting Person's continuous service through each such vesting date. F6 · derivative.expiration_date: The RSUs vest in four equal annual installments beginning February 17, 2027, subject to the Reporting Person's continuous service through each such vesting date. F1 · derivative.underlying: Ordinary Shares may be represented by American Depositary Shares. Each American Depositary Share represents one Ordinary Share. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 22:00 UTC | Immunocore Holdings plc IMCR · Entity 4544 | Exercise / conversionRestricted Share Units · Derivative | 1,351 | $0.00 | $0.00 |
DisclosureSEC source: 0001779466-26-000002 · form4-02192026_050207.xml · derivative · entry 3 GOLL JOHN · CIK 0001779466 · SVP, FINANCE & CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,054 Underlying: Ordinary Shares · 1,351 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one Ordinary Share. F5 · derivative.exercise_date: On February 17, 2025, the Reporting Person was granted 5,405 RSUs, vesting in four equal annual installments beginning February 17, 2026, subject to the Reporting Person's continuous service through each such vesting date. F5 · derivative.expiration_date: On February 17, 2025, the Reporting Person was granted 5,405 RSUs, vesting in four equal annual installments beginning February 17, 2026, subject to the Reporting Person's continuous service through each such vesting date. F1 · derivative.underlying: Ordinary Shares may be represented by American Depositary Shares. Each American Depositary Share represents one Ordinary Share. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 22:00 UTC | Immunocore Holdings plc IMCR · Entity 4544 | Exercise / conversionOrdinary Shares | 1,351 | $0.00 | $0.00 |
DisclosureSEC source: 0001779466-26-000002 · form4-02192026_050207.xml · nonDerivative · entry 1 GOLL JOHN · CIK 0001779466 · SVP, FINANCE & CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,351 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Ordinary Shares may be represented by American Depositary Shares. Each American Depositary Share represents one Ordinary Share. Read SEC document |
| February 17, 2025 Filed Feb 19, 2025 21:19 UTC | Immunocore Holdings plc IMCR · Entity 4544 | GrantRestricted Share Units · Derivative | 5,405 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-004607 · form4-02192025_090208.xml · derivative · entry 2 GOLL JOHN · CIK 0001779466 · SVP, FINANCE & CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,405 Underlying: Ordinary Shares · 5,405 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted share unit ("RSU") represents a contingent right to receive one ordinary share. F3 · derivative.exercise_date: The RSUs vest in four equal annual installments beginning February 17, 2026, subject to the Reporting Person's continuous service through each such vesting date. F3 · derivative.expiration_date: The RSUs vest in four equal annual installments beginning February 17, 2026, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| February 17, 2025 Filed Feb 19, 2025 21:19 UTC | Immunocore Holdings plc IMCR · Entity 4544 | GrantEmployee Share Option (Right to Buy) · Derivative | 14,802 | $0.00 Strike: $29.60 | $0.00 |
DisclosureSEC source: 0001415889-25-004607 · form4-02192025_090208.xml · derivative · entry 1 GOLL JOHN · CIK 0001779466 · SVP, FINANCE & CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,802 Underlying: Ordinary Shares · 14,802 shares Expires 2035-02-16 F1 · derivative.exercise_date: 25% of the shares subject to the option award shall vest on February 17, 2026, and 6.25% of the shares subject to the option award shall vest in quarterly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| February 16, 2024 Filed Feb 21, 2024 21:15 UTC | Immunocore Holdings plc IMCR · Entity 4544 | GrantEmployee Share Option (Right to Buy) · Derivative | 4,930 | $0.00 Strike: $70.50 | $0.00 |
DisclosureSEC source: 0001415889-24-004594 · form4-02212024_040229.xml · derivative · entry 1 GOLL JOHN · CIK 0001779466 · SVP, FINANCE & CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,930 Underlying: Ordinary Shares · 4,930 shares Expires 2034-02-15 F1 · derivative.exercise_date: 25% of the shares subject to the option award shall vest on February 16, 2025, and 6.25% of the shares subject to the option award shall vest in quarterly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| January 03, 2020 Filed Jan 7, 2020 23:11 UTC | INSMED Inc INSM · Entity 3174 | GrantStock Option (right to buy) · Derivative | 28,260 | $0.00 Strike: $23.75 | $0.00 |
DisclosureSEC source: 0001127430-20-000023 · edgar.xml · derivative · entry 3 GOLL JOHN · CIK 0001779466 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,260 Underlying: Common Stock · 28,260 shares Expires 2030-01-03 F5 · derivative.exercise_date: Stock options granted under the Company's 2019 Incentive Plan. The options become exercisable based on the following vesting schedule: twenty-five percent (25%) on the first anniversary of the grant date and an additional twelve and one-half percent (12.5%) vest on the six month anniversary of the first anniversary date and each six month anniversary date thereafter through the fourth anniversary of the date of grant. Read SEC document |
| January 03, 2020 Filed Jan 7, 2020 23:11 UTC | INSMED Inc INSM · Entity 3174 | Tax withholdingCommon Stock | 208 | $23.75 | $4,940.00 |
DisclosureSEC source: 0001127430-20-000023 · edgar.xml · nonDerivative · entry 2 GOLL JOHN · CIK 0001779466 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,166 F4 · price: Shares withheld by the Company to satisfy tax withholding requirements on vesting of time-based restricted stock units. Read SEC document |
| January 03, 2020 Filed Jan 7, 2020 23:11 UTC | INSMED Inc INSM · Entity 3174 | GrantCommon Stock | 5,263 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127430-20-000023 · edgar.xml · nonDerivative · entry 1 GOLL JOHN · CIK 0001779466 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,374 F1 · shares: Restricted stock units granted pursuant to the Company's 2019 Incentive Plan. The Restricted Stock Units vest and become available as follows: twenty five (25%) percent on each anniversary of the date of grant for four years. F2 · price: Each Restricted Stock Unit was granted on January 3, 2020, for no consideration, and represents a contingent right to receive one share of Common Stock. F3 · balance_after: Includes 2,751 shares acquired through the Company's 2018 Employee Stock Purchase Plan. Read SEC document |
| November 18, 2019 Filed Nov 20, 2019 21:10 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $12.58 | $0.00 |
DisclosureSEC source: 0001127430-19-000131 · edgar.xml · derivative · entry 3 GOLL JOHN · CIK 0001779466 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2024-06-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Stock options granted under the Company's 2013 Incentive Plan. These stock options are currently exercisable Read SEC document |
| November 18, 2019 Filed Nov 20, 2019 21:10 UTC | INSMED Inc INSM · Entity 3174 | SaleStock Option | 25,000 | $20.04 | $501,000.00 |
DisclosureSEC source: 0001127430-19-000131 · edgar.xml · nonDerivative · entry 2 GOLL JOHN · CIK 0001779466 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,322 F1 · price: This is the weighted average sales price representing 25,000 shares sold at prices ranging from $19.75 to $20.20 per share. The number sold at each price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request. Read SEC document |
| November 18, 2019 Filed Nov 20, 2019 21:10 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionStock Option | 25,000 | $12.58 | $314,500.00 |
DisclosureSEC source: 0001127430-19-000131 · edgar.xml · nonDerivative · entry 1 GOLL JOHN · CIK 0001779466 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,322 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.